1. In Vivo
  2. >>Archive

Zimmer Buys Abbott: Difficult Times Ahead in Spine

If spine is such a promising market, why did Abbott sell its spine business to Zimmer? The sale is a reflection of the transition period underway in the spine market, a transition born of a combination of the glut of small companies, the disappearance of large buyers, and also, some disappointments in some of spine's most promising technologies, And with that transition has come a perceptible loss of momentum in spine. For now that means depressed valuations on private financings for venture-backed spine companies and less-than-clear exits-an amazing turn around for an industry segment that just a couple of years ago looked strikingly different, certainly not the kind of spine industry Abbott thought it was buying into six years ago.

With the news last month that Abbott is selling its spine business to Zimmer for around $360 million, it may be hard to recall that less than two years ago Abbott was one of the finalists in the pricey sweepstakes to buy St. Francis Medical Technologies, losing out to Kyphon Inc. (now part of Medtronic PLC) in a deal that would eventually fetch $725 million or that, just four years earlier than that, Abbott Laboratories’ acquisition of Spinal Concepts (now Abbott Spine), was part of an ambitious plan to target the hot and fast-growing segment of spine devices as its next major play in medtech, following an earlier effort to build a cardiovascular franchise. [See Deal][See Deal]. (See "Spinal Concepts: Leading Abbott into the Spine Market," IN VIVO, July 2004 Also see "Spinal Concepts: Leading Abbott into the Spine Market" - In Vivo, 1 July, 2004..)

Indeed, six years ago, when Abbott bought Spinal Concepts to get into spine, the deal seemed rich in promise, notwithstanding...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By Eleanor Malone

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Early Development Deals: Ipsen's Strategy For Biomarker-Driven Success

 
• By Eliza Slawther

Mary Jane Hinrichs, Ipsen’s head of early development, talks to In Vivo about getting ahead of the competition by securing deals for candidates before they enter Phase I trials.   

Shape Our Content: Take The Reader Survey

 
• By Eleanor Malone

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access In Vivo, or if you love it how it is, now is the time to have your voice heard.

In Partnership with Cerba Research

Prioritizing Safety in CAR-T Therapy: Patient Monitoring with Cerba Research’s Testing Portfolio

The cell and gene therapy (CGT) clinical trial landscape in general and CAR-T cell clinical trials in particular are a special focus for the FDA, EMA, and other regulatory agencies. The whole industry is thus aware of the recent FDA safety investigation and requirements for labeling CAR therapy products.

More from In Vivo

AI In Health Delivery: Patients Most Confident When HCPs Are In Charge

 
• By Ashley Yeo

Annual survey of patients and professionals shows how attitudes to health system transformation are evolving and what stakeholders are demanding as acceptance of AI tools accelerates.

Medtech Innovators Court London-Based Investors At BioWales 2025

 
• By Ashley Yeo

BioWales in London 2025 showcased the efforts healthtech innovators are making to meet investors on their own turf, illustrating changing attitudes and evolving needs.

Rising Leaders 2025: Metsera’s Whit Bernard’s Musical Path To Biotech Leadership

 
• By David Wild

Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.